ERBB2 and glioblastoma: Several other early phase clinical trials with CAR-engineered NK-92 cells are presently ongoing in Europe, China and the US (15, 83), including the CAR2BRAIN phase I clinical study which investigates a clonal ErbB2-specific CAR NK-92 product in glioblastoma patients and is described in more detail in a subsequent section (125, 162).